High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
McGrail, D.J., Pilié, P.G., Rashid, N.U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A.B., Lim, B., Ueno, N.T., Litton, J.K., Ferrarotto, R., Chang, J.T., Moulder, S.L., Lin, S.-Y.
Published in Annals of oncology (01.05.2021)
Published in Annals of oncology (01.05.2021)
Get full text
Journal Article
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence
Mittendorf, E.A., Ardavanis, A., Symanowski, J., Murray, J.L., Shumway, N.M., Litton, J.K., Hale, D.F., Perez, S.A., Anastasopoulou, E.A., Pistamaltzian, N.F., Ponniah, S., Baxevanis, C.N., von Hofe, E., Papamichail, M., Peoples, G.E.
Published in Annals of oncology (01.07.2016)
Published in Annals of oncology (01.07.2016)
Get full text
Journal Article
Significant Improvement in Regional Recurrence in Young Patients with Breast Cancer Treated with Comprehensive Nodal Irradiation
Woodward, W.A, Beadle, B.M, Oh, J.L, Tereffe, W, Litton, J.K, Perkins, G.H, Strom, E.A, Yu, T, Meric-Bernstam, F, Buchholz, T.A
Published in International journal of radiation oncology, biology, physics (2008)
Published in International journal of radiation oncology, biology, physics (2008)
Get full text
Journal Article
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
Litton, J.K., Hurvitz, S.A., Mina, L.A., Rugo, H.S., Lee, K.-H., Gonçalves, A., Diab, S., Woodward, N., Goodwin, A., Yerushalmi, R., Roché, H., Im, Y.-H., Eiermann, W., Quek, R.G.W., Usari, T., Lanzalone, S., Czibere, A., Blum, J.L., Martin, M., Ettl, J.
Published in Annals of oncology (01.11.2020)
Published in Annals of oncology (01.11.2020)
Get full text
Journal Article
Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer
Fujii, T., Kogawa, T., Dong, W., Sahin, A.A., Moulder, S., Litton, J.K., Tripathy, D., Iwamoto, T., Hunt, K.K., Pusztai, L., Lim, B., Shen, Y., Ueno, N.T.
Published in Annals of oncology (01.10.2017)
Published in Annals of oncology (01.10.2017)
Get full text
Journal Article
Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial
Ettl, J., Quek, R.G.W., Lee, K.-H., Rugo, H.S., Hurvitz, S., Gonçalves, A., Fehrenbacher, L., Yerushalmi, R., Mina, L.A., Martin, M., Roché, H., Im, Y.-H., Markova, D., Bhattacharyya, H., Hannah, A.L., Eiermann, W., Blum, J.L., Litton, J.K.
Published in Annals of oncology (01.09.2018)
Published in Annals of oncology (01.09.2018)
Get full text
Journal Article
21P Germline and somatic variants in DNA DMAGE repair (DDR) genes in patients with untreated, early-stage triple negative breast cancers (TNBC)
Litton, J.K., Zhao, L., White, J., Arun, B., Ravenberg, E., Song, X., Zhang, J., Moulder, S.
Published in Annals of oncology (01.05.2020)
Published in Annals of oncology (01.05.2020)
Get full text
Journal Article
337 (PB325): Poly(ADP-Ribose) Polymerase (PARP) inhibition in metastatic breast cancer: comparison of therapeutic outcomes between patients with BRCA1/2 mutations and other alterations
Coleman, N., Ngoi, N.Y.L., Nguyen, D., Nelson, B., Dumbrava, E., Fu, S., Hong, D.S., Karp, D., Naing, A., Piha-Paul, S.A., Rodon, J., Tsimberidou, A., Lim, B., Pohlman, P., Meric-Bernstam, F., Litton, J.K., Arun, B., Yap, T.A.
Published in European journal of cancer (1990) (01.10.2024)
Published in European journal of cancer (1990) (01.10.2024)
Get full text
Journal Article
272P Outcomes of patients (pts) who had received prior platinum (PP) therapy in the phase III EMBRACA trial of talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC)
Martin, M., Rugo, H.S., Hurvitz, S.A., Ettl, J., Roche, H., Lee, K-H., Goodwin, A., Usari, T., Lanzalone, S., Guenzel, C.A., Blum, J., Litton, J.K.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
273P Talazoparib (TALA) for patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC): Characteristics of patients who experienced hematologic toxicity in the phase III EMBRACA trial
Hurvitz, S.A., Rugo, H.S., Ettl, J., Martin, M., Roche, H., Lee, K-H., Goodwin, A., Usari, T., Lanzalone, S., Guenzel, C.A., Blum, J., Litton, J.K.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
383TiP - Bintrafusp alfa (M7824) and eribulin mesylate in treating patients with metastatic triple negative breast cancer (TNBC)(NCT03579472)
Litton, J.K., Damodaran, S., Wistuba, I.I., Yang, F., Contreras, A., Tam, A., Ojalvo, L., Dussault, I., Helwig, C., Moulder, S.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Bintrafusp alfa (M7824) and eribulin mesylate in treating patients with metastatic triple negative breast cancer (TNBC)(NCT03579472)
Litton, J.K., Damodaran, S., Wistuba, I.I., Yang, F., Contreras, A., Tam, A., Ojalvo, L., Dussault, I., Helwig, C., Moulder, S.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
98O The immunomodulatory (IM) signature enhances prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple negative breast cancers (TNBC) with moderate stromal tumour infiltrating lymphocytes (sTIL)
Abuhadra, N., Sun, R., Litton, J.K., Rauch, G., Thompson, A.M., Lim, B., Adrada, B., Mittendorf, E., Damodaran, S., Pitpitan, R., Arun, B., White, J., Ravenberg, E., Santiago, L., Sahin, A., Murthy, R., Ueno, N.T., Ibrahim, N., Moulder, S., Huo, L.
Published in Annals of oncology (01.05.2020)
Published in Annals of oncology (01.05.2020)
Get full text
Journal Article
Exploration of markers of synergistic lethality of PARP and PI3K-akt-mTOR inhibitors in women’s cancers
Labrie, M., Ju, Z., Litton, J.K., Kim, T.B., Lee, S., Chen, K., Soliman, P.T., Frumovitz, M., Meyer, L.A., Moulder, S., Jazaeri, A.A., Lu, K.H., Sood, A.K., Coleman, R.L., Mills, G.B., Westin, S.N.
Published in Gynecologic oncology (01.06.2019)
Published in Gynecologic oncology (01.06.2019)
Get full text
Journal Article
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer
Gonzalez-Angulo, A.M., Akcakanat, A., Liu, S., Green, M.C., Murray, J.L., Chen, H., Palla, S.L., Koenig, K.B., Brewster, A.M., Valero, V., Ibrahim, N.K., Moulder-Thompson, S., Litton, J.K., Tarco, E., Moore, J., Flores, P., Crawford, D., Dryden, M.J., Symmans, W.F., Sahin, A., Giordano, S.H., Pusztai, L., Do, K.-A., Mills, G.B., Hortobagyi, G.N., Meric-Bernstam, F.
Published in Annals of oncology (01.06.2014)
Published in Annals of oncology (01.06.2014)
Get full text
Journal Article
Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial
Yu, Y., Elmeliegy, M., Litton, J.K., Tudor, I.C., Czibere, A., Zheng, J., Wang, D.D.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer
Kim, M.M., Allen, P., Gonzalez-Angulo, A.M., Woodward, W.A., Meric-Bernstam, F., Buzdar, A.U., Hunt, K.K., Kuerer, H.M., Litton, J.K., Hortobagyi, G.N., Buchholz, T.A., Mittendorf, E.A.
Published in Annals of oncology (01.08.2013)
Published in Annals of oncology (01.08.2013)
Get full text
Journal Article
Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials
Elmeliegy, M., Yu, Y., Litton, J.K., Turner, N.C., Czibere, A., Wilson, G.G., Tudor, I.C., Zheng, J., Wang, D.D.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulation
Rugo, H.S., Quek, R., Ettl, J., Hurvitz, S.A., Bhattacharyya, H., Hannah, A.L., Litton, J.K.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article